Quarterly Financial Performance: A Positive Shift
The December 2025 quarter marked a pivotal moment for Mukka Proteins, with the company’s financial trend score improving dramatically from -8 to +15 over the past three months. This shift reflects a robust recovery in profitability and sales volumes, underscoring the effectiveness of recent strategic initiatives.
Net sales for the quarter reached an all-time high of ₹653.50 crores, a clear indication of strong market demand and effective distribution channels. This figure represents a substantial increase compared to the previous four-quarter average, signalling that Mukka Proteins is successfully expanding its footprint in the competitive FMCG landscape.
Profit before depreciation, interest, and taxes (PBDIT) also surged to a record ₹45.44 crores, highlighting improved operational efficiency and cost management. Correspondingly, profit before tax excluding other income (PBT less OI) climbed to ₹29.69 crores, the highest level recorded by the company in recent quarters.
Profit After Tax (PAT) Growth: Doubling Performance
One of the most striking aspects of Mukka Proteins’ quarterly results is the 101.1% growth in PAT, which stood at ₹23.75 crores. This doubling of net profit compared to the previous four-quarter average is a testament to the company’s enhanced profitability and margin expansion efforts. Such a leap in PAT is particularly noteworthy given the challenging macroeconomic environment and rising input costs faced by FMCG companies.
Rising Interest Costs: A Cautionary Note
Despite the positive earnings momentum, Mukka Proteins recorded its highest quarterly interest expense at ₹14.56 crores. This increase in finance costs warrants close monitoring, as it could potentially weigh on net margins if not addressed through deleveraging or refinancing strategies. Investors should consider this factor when evaluating the sustainability of the company’s profit growth.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Stock Price and Market Performance
Mukka Proteins’ stock price closed at ₹25.01 on 13 Feb 2026, down 1.61% from the previous close of ₹25.42. The stock traded within a range of ₹24.82 to ₹26.04 during the day, reflecting some volatility amid broader market movements. The 52-week high and low stand at ₹35.93 and ₹20.20 respectively, indicating a wide trading band over the past year.
From a returns perspective, Mukka Proteins has outperformed the Sensex over shorter time frames. The stock delivered a 12.4% return over the past month compared to a 0.85% decline in the Sensex. Year-to-date, the stock is up 4.16%, while the benchmark index has fallen 2.71%. However, over the trailing one-year period, Mukka Proteins has underperformed significantly with a negative return of 28.44%, against the Sensex’s 8.90% gain. This mixed performance highlights the stock’s volatility and the importance of monitoring ongoing financial trends.
Mojo Score and Rating Upgrade
Reflecting the improved financial trajectory, Mukka Proteins’ Mojo Score has risen to 51.0, prompting an upgrade in its Mojo Grade from Sell to Hold as of 14 Nov 2025. This upgrade signals a cautious optimism among analysts, recognising the company’s recent operational improvements while acknowledging lingering risks such as elevated interest expenses and competitive pressures in the FMCG sector.
Industry and Sector Context
Operating within the FMCG sector, Mukka Proteins faces intense competition and fluctuating raw material costs. The sector has generally experienced moderate growth, with many companies focusing on margin expansion through product innovation and supply chain optimisation. Mukka Proteins’ recent quarterly results suggest it is beginning to capitalise on these trends, although sustaining this momentum will require continued focus on cost control and market penetration.
Mukka Proteins Ltd or something better? Our SwitchER feature analyzes this micro-cap FMCG stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Outlook and Investor Considerations
Looking ahead, Mukka Proteins’ ability to maintain its positive financial trend will be critical. The company’s recent surge in sales and profitability is encouraging, but investors should remain vigilant regarding the rising interest burden and the broader economic environment impacting consumer spending.
Given the current Mojo Grade of Hold, investors may consider a cautious approach, balancing the company’s growth potential against sector risks and valuation metrics. The stock’s recent outperformance relative to the Sensex in the short term is a positive indicator, but the significant underperformance over the last year suggests volatility remains a factor.
Overall, Mukka Proteins appears to be on a recovery path, with its latest quarterly results providing a foundation for potential future gains. Continued monitoring of quarterly updates and sector developments will be essential for making informed investment decisions.
Unlock special upgrade rates for a limited period. Start Saving Now →
